CLAIMS

1. A solid form of compound 1,



1;

wherein said solid form is a crystalline form A2,

wherein said form A2 is characterized by the following 2θ XRPD peaks at 4.7, 9.4, 15.0, 17.5, 17.9, 19.0, 19.7, 20.6 and 23.4 ± 0.2 degrees under the following conditions: monochromatic Cu-Kα_1 radiation, λ= 1.5406 Å; or

wherein said form A2 is characterized by a crystal form, having a monoclinic space group $P2_1$ with the lattice parameters (at 200 K) a = 9.4±0.1 Å, b = 37.2±0.2 Å, c = 12.8±0.1 Å, and β = 91.9±0.5° (with $\alpha = \gamma = 90°$).

2. ~~The~~ A solid form of ~~claim 1~~compound 1,



1;

wherein said solid form is characterized as a mixture of crystalline forms A1 and A2;

wherein said crystalline form A1 is characterized by the following 2θ XRPD peaks at 4.8, 9.5, 15.1, 17.4, 18.1, 20.0, and 23.8 ± 0.2 degrees under the following conditions: monochromatic Cu-Kα_1 radiation, λ= 1.5406 Å: or

wherein said crystalline form A1 is characterized by a crystal form, having a monoclinic space group $P2_1$ with the lattice parameters (at 200 K) a = 12.8±0.1 Å, b = 9.4±0.1 Å, c = 37.3±0.2 Å, and β = 98.5±0.5° (with α = γ = 90°).; and

wherein said form A2 is characterized by the following 2θ XRPD peaks at 4.7, 9.4, 15.0, 17.5, 17.9, 19.0, 19.7, 20.6 and 23.4 ± 0.2 degrees under the following conditions: monochromatic Cu-Kα_1 radiation, λ= 1.5406 Å; or

wherein said form A2 is characterized by a crystal form, having a monoclinic space group $P2_1$ with the lattice parameters (at 200 K) a = 9.4±0.1 Å, b = 37.2±0.2 Å, c = 12.8±0.1 Å, and β = 91.9±0.5° (with α = γ = 90°).

3. A pharmaceutical composition, comprising:

a solid form of compound 1 of claim 1 or 2, and

a pharmaceutically acceptable adjuvant, carrier, or vehicle.

4. A solid form of compound 1 of claim 1 or 2 for use in treating a BTK-mediated disorder in a patient in need thereof,

wherein said BTK-mediated disorder is systemic lupus erythematosus (SLE), multiple sclerosis, or rheumatoid arthritis.